Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-200c-3p ACTC1 3.5 0 -7.19 0 MirTarget -1.34 0 NA
2 hsa-miR-200c-3p ADAMTS3 3.5 0 -1.18 0.00448 miRNATAP -0.41 0 NA
3 hsa-miR-200c-3p ADCY2 3.5 0 -3.87 0 MirTarget; miRNATAP -0.44 0 NA
4 hsa-miR-200c-3p AFF3 3.5 0 -5 0 MirTarget; miRNATAP -0.59 0 NA
5 hsa-miR-200c-3p AP1S2 3.5 0 -1.31 0 MirTarget; miRNATAP -0.38 0 NA
6 hsa-miR-200c-3p ARHGAP20 3.5 0 -3.52 0 MirTarget; miRNATAP -0.51 0 NA
7 hsa-miR-200c-3p BACH2 3.5 0 -1.52 0.00134 mirMAP -0.54 0 NA
8 hsa-miR-200c-3p BEND4 3.5 0 -1.97 7.0E-5 mirMAP -0.32 0 NA
9 hsa-miR-200c-3p BNC2 3.5 0 -2.95 0 MirTarget -0.7 0 NA
10 hsa-miR-200c-3p C11orf87 3.5 0 -1.55 0.01186 miRNATAP -0.34 0 NA
11 hsa-miR-200c-3p CACNA1C 3.5 0 -2.53 0 MirTarget -0.44 0 NA
12 hsa-miR-200c-3p CDK6 3.5 0 -0.77 0.06479 mirMAP -0.32 0 NA
13 hsa-miR-200c-3p CELF2 3.5 0 -3.05 0 mirMAP; miRNATAP -0.51 0 NA
14 hsa-miR-200c-3p CFL2 3.5 0 -2.62 0 MirTarget; miRNATAP -0.48 0 23497265 We characterized one of the target genes of miR-200c CFL2 and demonstrated that CFL2 is overexpressed in aggressive breast cancer cell lines and can be significantly down-regulated by exogenous miR-200c
15 hsa-miR-200c-3p CHRDL1 3.5 0 -6.15 0 MirTarget -0.99 0 NA
16 hsa-miR-200c-3p CHST11 3.5 0 0.54 0.2311 mirMAP -0.4 0 NA
17 hsa-miR-200c-3p CLIC4 3.5 0 -1.72 0 MirTarget; miRNATAP -0.46 0 NA
18 hsa-miR-200c-3p CNTFR 3.5 0 -3.86 0 miRNATAP -0.44 0 NA
19 hsa-miR-200c-3p CNTN1 3.5 0 -4.98 0 MirTarget; miRNATAP -0.74 0 NA
20 hsa-miR-200c-3p COL4A3 3.5 0 -3.14 0 miRNATAP -0.32 0 NA
21 hsa-miR-200c-3p CREB5 3.5 0 -2.28 0 miRNATAP -0.47 0 NA
22 hsa-miR-200c-3p CYP1B1 3.5 0 -2.82 0 miRNATAP -0.55 0 25860934 Loss of miR 200c up regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma; Additionally miR-200c which is significantly down-regulated in RCC regulates CYP1B1 expression and activity; An inverse association was also observed between the expression levels of miR-200c and CYP1B1 protein in RCC tissues; Restoration of docetaxel resistance by exogenous expression of CYP1B1 in miR-200c-over-expressing cells indicates that CYP1B1 is a functional target of miR-200c; These results suggest that CYP1B1 up-regulation mediated by low miR-200c is one of the mechanisms underlying resistance of RCC cells to docetaxel; Therefore expression of CYP1B1 and miR-200c in RCC may be useful as a prediction for docetaxel response
23 hsa-miR-200c-3p DACT1 3.5 0 -1.78 2.0E-5 miRNATAP -0.47 0 NA
24 hsa-miR-200c-3p DCBLD2 3.5 0 -0.13 0.73597 MirTarget -0.31 0 NA
25 hsa-miR-200c-3p DDIT4L 3.5 0 -1.9 0.00047 MirTarget -0.47 0 NA
26 hsa-miR-200c-3p DENND5B 3.5 0 -1.35 0.0001 MirTarget; miRNATAP -0.39 0 NA
27 hsa-miR-200c-3p DIXDC1 3.5 0 -3.01 0 MirTarget -0.52 0 NA
28 hsa-miR-200c-3p DMD 3.5 0 -3.69 0 miRNATAP -0.53 0 NA
29 hsa-miR-200c-3p DNAJB5 3.5 0 -2.65 0 miRNATAP -0.52 0 NA
30 hsa-miR-200c-3p DRP2 3.5 0 -1.35 0.00023 mirMAP -0.31 0 NA
31 hsa-miR-200c-3p DTNA 3.5 0 -4.06 0 MirTarget -0.65 0 NA
32 hsa-miR-200c-3p DUSP1 3.5 0 -3.47 0 MirTarget; miRNATAP -0.32 0 NA
33 hsa-miR-200c-3p DZIP1 3.5 0 -1.57 2.0E-5 MirTarget -0.34 0 NA
34 hsa-miR-200c-3p EDNRA 3.5 0 -2.19 0 miRNAWalker2 validate; miRNATAP -0.43 0 NA
35 hsa-miR-200c-3p F2RL2 3.5 0 -0.07 0.88286 MirTarget -0.4 0 NA
36 hsa-miR-200c-3p FBLN5 3.5 0 -2.76 0 miRNAWalker2 validate; miRTarBase -0.4 0 NA
37 hsa-miR-200c-3p FGF2 3.5 0 -3.46 0 mirMAP -0.58 0 NA
38 hsa-miR-200c-3p FHL1 3.5 0 -4.79 0 MirTarget -0.78 0 NA
39 hsa-miR-200c-3p FLI1 3.5 0 -1.11 7.0E-5 MirTarget; miRNATAP -0.32 0 NA
40 hsa-miR-200c-3p FLNA 3.5 0 -2.63 0 miRNAWalker2 validate -0.57 0 NA
41 hsa-miR-200c-3p FN1 3.5 0 -0.41 0.45793 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.66 0 NA
42 hsa-miR-200c-3p FOXF1 3.5 0 -3.6 0 MirTarget -0.33 0 NA
43 hsa-miR-200c-3p FSTL1 3.5 0 -1.2 3.0E-5 MirTarget -0.36 0 NA
44 hsa-miR-200c-3p FYN 3.5 0 -1.47 0 miRNATAP -0.35 0 NA
45 hsa-miR-200c-3p GEM 3.5 0 -3.69 0 MirTarget; miRNATAP -0.6 0 NA
46 hsa-miR-200c-3p GFRA1 3.5 0 -5 0 mirMAP -0.33 0 NA
47 hsa-miR-200c-3p GJC1 3.5 0 -0.97 0.00222 MirTarget; miRNATAP -0.31 0 NA
48 hsa-miR-200c-3p GLIS2 3.5 0 -0.61 0.05279 miRNATAP -0.31 0 NA
49 hsa-miR-200c-3p GNG4 3.5 0 0.22 0.74468 mirMAP -0.42 0 NA
50 hsa-miR-200c-3p GPM6A 3.5 0 -4.43 0 miRNATAP -0.61 0 NA
51 hsa-miR-200c-3p GREM1 3.5 0 0.09 0.91453 MirTarget -0.65 0 NA
52 hsa-miR-200c-3p HLF 3.5 0 -5.48 0 MirTarget; miRNATAP -0.6 0 NA
53 hsa-miR-200c-3p HS3ST3A1 3.5 0 -0.13 0.83157 MirTarget -0.63 0 NA
54 hsa-miR-200c-3p IGSF10 3.5 0 -5.3 0 MirTarget -0.54 0 NA
55 hsa-miR-200c-3p IL6ST 3.5 0 -2.1 2.0E-5 mirMAP -0.35 0 NA
56 hsa-miR-200c-3p ITGA1 3.5 0 -1.43 0 MirTarget -0.34 0 NA
57 hsa-miR-200c-3p ITPR1 3.5 0 -2.58 0 miRNATAP -0.31 0 NA
58 hsa-miR-200c-3p JAZF1 3.5 0 -1.92 0 MirTarget; miRNATAP -0.42 0 NA
59 hsa-miR-200c-3p KCNK2 3.5 0 -3.96 0 miRNATAP -0.5 0 NA
60 hsa-miR-200c-3p KCNQ4 3.5 0 -2.64 0 miRNATAP -0.36 0 NA
61 hsa-miR-200c-3p KIAA1462 3.5 0 -1.72 0 MirTarget -0.39 0 NA
62 hsa-miR-200c-3p KLF9 3.5 0 -2.79 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.4 0 NA
63 hsa-miR-200c-3p LHFP 3.5 0 -1.83 0 MirTarget; miRNATAP -0.36 0 NA
64 hsa-miR-200c-3p LIX1L 3.5 0 -1.29 0 MirTarget -0.34 0 NA
65 hsa-miR-200c-3p MAF 3.5 0 -1.28 0.00016 miRNATAP -0.36 0 NA
66 hsa-miR-200c-3p MFAP5 3.5 0 -4.35 0 miRNATAP -0.9 0 NA
67 hsa-miR-200c-3p MITF 3.5 0 -2.11 0 miRNATAP -0.37 0 NA
68 hsa-miR-200c-3p MMD 3.5 0 -0.05 0.87055 miRNATAP -0.31 0 NA
69 hsa-miR-200c-3p MRVI1 3.5 0 -3.2 0 MirTarget -0.43 0 NA
70 hsa-miR-200c-3p MSN 3.5 0 -0.86 0.01366 miRNAWalker2 validate; miRTarBase; MirTarget -0.39 0 NA
71 hsa-miR-200c-3p MSRB3 3.5 0 -3.32 0 mirMAP -0.64 0 NA
72 hsa-miR-200c-3p NCAM1 3.5 0 -5.47 0 miRTarBase -0.87 0 NA
73 hsa-miR-200c-3p NCS1 3.5 0 -1.74 0 miRNATAP -0.3 0 NA
74 hsa-miR-200c-3p NEGR1 3.5 0 -4.78 0 miRNATAP -0.68 0 NA
75 hsa-miR-200c-3p NFASC 3.5 0 -2.96 0 miRNATAP -0.3 0 23185507 miR 200c targets a NF κB up regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer
76 hsa-miR-200c-3p NOG 3.5 0 -1.05 0.08272 MirTarget; miRNATAP -0.38 0 NA
77 hsa-miR-200c-3p NOVA1 3.5 0 -4.22 0 MirTarget; miRNATAP -0.42 0 NA
78 hsa-miR-200c-3p NR3C1 3.5 0 -1.29 4.0E-5 miRNATAP -0.31 0 NA
79 hsa-miR-200c-3p NRG1 3.5 0 -1.24 0.07417 miRNATAP -0.39 0 NA
80 hsa-miR-200c-3p NTRK2 3.5 0 -3.44 0 miRNAWalker2 validate; miRTarBase -0.56 0 23209748; 23074172 miR 200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression;miR-200c also targets TrkB a mediator of resistance to anoikis
81 hsa-miR-200c-3p PALM2-AKAP2 3.5 0 -1.62 0 miRNATAP -0.42 0 NA
82 hsa-miR-200c-3p PCDH10 3.5 0 -3.24 0 MirTarget -0.53 0 NA
83 hsa-miR-200c-3p PCSK2 3.5 0 -6.63 0 miRNATAP -0.39 0 NA
84 hsa-miR-200c-3p PDE5A 3.5 0 -2.72 0 miRNATAP -0.3 0 NA
85 hsa-miR-200c-3p PLCL1 3.5 0 -2.36 0 MirTarget -0.41 0 NA
86 hsa-miR-200c-3p PLXNA4 3.5 0 -2.25 5.0E-5 miRNATAP -0.68 0 NA
87 hsa-miR-200c-3p PLXNC1 3.5 0 -0.53 0.2847 miRNATAP -0.43 0 NA
88 hsa-miR-200c-3p PPARGC1A 3.5 0 -4.12 0 mirMAP -0.48 0 NA
89 hsa-miR-200c-3p PPP2R2C 3.5 0 -0.8 0.26616 miRNATAP -0.31 4.0E-5 NA
90 hsa-miR-200c-3p PRKAA2 3.5 0 -3.17 0 MirTarget -0.32 0 NA
91 hsa-miR-200c-3p PRKCB 3.5 0 -3.26 0 MirTarget; miRNATAP -0.49 0 NA
92 hsa-miR-200c-3p PRKG1 3.5 0 -3.09 0 miRNATAP -0.56 0 NA
93 hsa-miR-200c-3p PTHLH 3.5 0 -0.64 0.35954 MirTarget -0.32 1.0E-5 NA
94 hsa-miR-200c-3p PTPRD 3.5 0 -3.63 0 miRNAWalker2 validate -0.63 0 NA
95 hsa-miR-200c-3p PTPRZ1 3.5 0 -3.07 0.00082 MirTarget; miRNATAP -0.42 1.0E-5 NA
96 hsa-miR-200c-3p PYGO1 3.5 0 -2.1 4.0E-5 mirMAP -0.41 0 NA
97 hsa-miR-200c-3p RASSF8 3.5 0 -1.49 0 miRNATAP -0.31 0 NA
98 hsa-miR-200c-3p RECK 3.5 0 -2.39 0 miRNATAP -0.45 0 27574450; 24647918 MiR 200c promotes bladder cancer cell migration and invasion by directly targeting RECK; The luciferase reporter assay showed that RECK was a direct target of miR-200c;Finally we demonstrated that expression of miR-200c in H460 cells suppressed cell growth by targeting RECK followed by activation of the JNK signaling pathway and ER stress; Collectively these data show that miR-200c expression sensitizes H460 cells to RESV and this is likely due to RECK expression
99 hsa-miR-200c-3p REEP1 3.5 0 -4.35 0 MirTarget; miRNATAP -0.61 0 NA
100 hsa-miR-200c-3p RELN 3.5 0 -4.7 0 MirTarget -0.65 0 NA
101 hsa-miR-200c-3p RUSC2 3.5 0 -1.6 0 miRNATAP -0.33 0 NA
102 hsa-miR-200c-3p SCN3A 3.5 0 -2.33 0 mirMAP -0.32 0 NA
103 hsa-miR-200c-3p SCUBE3 3.5 0 -2.48 0 mirMAP -0.39 0 NA
104 hsa-miR-200c-3p SDC2 3.5 0 -2.01 0 miRNATAP -0.33 0 NA
105 hsa-miR-200c-3p SFMBT2 3.5 0 -1.41 0.00042 mirMAP -0.35 0 NA
106 hsa-miR-200c-3p SGCD 3.5 0 -3.55 0 mirMAP -0.67 0 NA
107 hsa-miR-200c-3p SGIP1 3.5 0 -0.44 0.23102 MirTarget -0.32 0 NA
108 hsa-miR-200c-3p SHE 3.5 0 -2.12 0 mirMAP -0.35 0 NA
109 hsa-miR-200c-3p SIRPA 3.5 0 -0.55 0.11927 MirTarget -0.38 0 NA
110 hsa-miR-200c-3p SLC16A12 3.5 0 -0.98 0.04552 mirMAP; miRNATAP -0.31 0 NA
111 hsa-miR-200c-3p SLC16A2 3.5 0 -1.54 0 miRNATAP -0.4 0 NA
112 hsa-miR-200c-3p SLC30A4 3.5 0 -1.13 0.0037 mirMAP -0.37 0 NA
113 hsa-miR-200c-3p SLC6A17 3.5 0 0.94 0.05681 mirMAP; miRNATAP -0.34 0 NA
114 hsa-miR-200c-3p SNAP25 3.5 0 -1.15 0.03273 MirTarget; miRNATAP -0.46 0 NA
115 hsa-miR-200c-3p STARD8 3.5 0 -1.76 0 mirMAP -0.38 0 NA
116 hsa-miR-200c-3p SULF1 3.5 0 0.17 0.75761 MirTarget; miRNATAP -0.5 0 NA
117 hsa-miR-200c-3p SV2B 3.5 0 -2.33 7.0E-5 mirMAP -0.6 0 NA
118 hsa-miR-200c-3p SYDE1 3.5 0 -0.81 0.00222 MirTarget; miRNATAP -0.36 0 NA
119 hsa-miR-200c-3p SYT11 3.5 0 -2.12 0 mirMAP -0.47 0 NA
120 hsa-miR-200c-3p TBX18 3.5 0 -2.2 0.00125 MirTarget -0.48 0 NA
121 hsa-miR-200c-3p TCF4 3.5 0 -1.61 0 mirMAP; miRNATAP -0.32 0 NA
122 hsa-miR-200c-3p TCF7L1 3.5 0 -1.3 0.00022 miRNAWalker2 validate -0.32 0 NA
123 hsa-miR-200c-3p TFEC 3.5 0 0.02 0.97058 MirTarget -0.38 0 NA
124 hsa-miR-200c-3p THEMIS 3.5 0 -1.31 0.01187 mirMAP -0.31 0 NA
125 hsa-miR-200c-3p TIMP2 3.5 0 -1.75 1.0E-5 miRTarBase -0.48 0 NA
126 hsa-miR-200c-3p TUBB2A 3.5 0 -0.68 0.0629 MirTarget; miRNATAP -0.3 0 NA
127 hsa-miR-200c-3p VAT1L 3.5 0 -1.21 0.00422 MirTarget; miRNATAP -0.3 0 NA
128 hsa-miR-200c-3p WIPF1 3.5 0 -1.36 1.0E-5 MirTarget; miRNATAP -0.42 0 NA
129 hsa-miR-200c-3p ZCCHC24 3.5 0 -2.71 0 MirTarget; miRNATAP -0.47 0 NA
130 hsa-miR-200c-3p ZDHHC15 3.5 0 -2.82 0 MirTarget -0.37 0 NA
131 hsa-miR-200c-3p ZEB1 3.5 0 -2.59 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.49 0 27666124; 24710933; 23754305; 24615544; 24424572; 24186205; 21682933; 22407310; 27717206; 23626803 miR 200c regulates crizotinib resistant ALK positive lung cancer cells by reversing epithelial mesenchymal transition via targeting ZEB1;miR-200c has been shown to regulate the epithelial-mesenchymal transition EMT by inhibiting ZEB1 and ZEB2 expression in breast cancer cells; This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression;Overexpression of miR-200c in SN12-PM6 and 786-0 cells was concurrent with downregulation of ZEB1 and upregulation of E-cadherin mRNA and protein; Thus our study demonstrated that miR-200c decreases the metastatic ability of renal carcinoma cells by upregulating E-cadherin through ZEB1 and that modulating the expression of miR-200c could influence Akt protein levels;MiR 200c suppresses TGF β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer; MiR-200c which was the most significantly downregulated miRNA in trastuzumab-resistant cells restored trastuzumab sensitivity and suppressed invasion of breast cancer cells by concurrently targeting ZNF217 a transcriptional activator of TGF-β and ZEB1 a known mediator of TGF-β signaling; Given the reported backward inhibition of miR-200c by ZEB1 ZNF217 also exerts a feedback suppression of miR-200c via TGF-β/ZEB1 signaling; Restoration of miR-200c silencing of ZEB1 or ZNF217 or blockade of TGF-β signaling increased trastuzumab sensitivity and suppressed invasiveness of breast cancer cells;Accordingly the enforced expression of miR-200c and mir-141 resulted in a significant upregulation in E-cadherin expression contrary to the significant downregulation in ZEB1 expression in 3 cell lines UTSCC-24A UTSCC-24B and UTSCC-6A cells;Furthermore miR-200c was found to be important in modulating ZEB1 upregulation by ERG;Of this family miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2 mediators of epithelial- mesenchymal transition;miR 200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1; Among those dysregulated microRNAs miR-200c was speculated to inhibit metastasis by targeting ZEB1; Overexpression of miR-200c was concurrent with downregulation of ZEB1 mRNA and protein; Taken together our study demonstrated that miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic tool for inhibiting metastasis in colorectal cancer;Epigenetic Silencing of miR 200c in Breast Cancer Is Associated with Aggressiveness and Is Modulated by ZEB1;Concomitant with the increase in miR-200b and miR-200c ZEB1 expression was decreased and cells appeared more epithelial in morphology and were sensitized to TAM and fulvestrant inhibition
132 hsa-miR-200c-3p ZEB2 3.5 0 -2.26 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.51 0 24710933; 26935975; 21682933; 25052237; 18925646; 24885194 miR-200c has been shown to regulate the epithelial-mesenchymal transition EMT by inhibiting ZEB1 and ZEB2 expression in breast cancer cells; This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression;MicroRNA 200c inhibits the metastasis of non small cell lung cancer cells by targeting ZEB2 an epithelial mesenchymal transition regulator;Of this family miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2 mediators of epithelial- mesenchymal transition;miR 200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E box binding homeobox 2 ZEB2 expression; Luciferase reporter assay confirmed the target of miR-200c as ZEB2; Furthermore miR-200c expression inhibited ovarian cancer cell ES-2 migration and invasion capacity by suppression of ZEB2 expression p < 0.01; Thus targeting of miR-200c or ZEB2 may serve as a potential therapeutic strategy for control of ovarian cancer;We established by quantitative RT-PCR that in CCCs in which miR-141 and miR-200c were down-regulated ZFHX1B a transcriptional repressor for CDH1/E-cadherin tended to be up-regulated; On the basis of these findings we suggest that down-regulation of miR-141 and miR-200c in CCCs might be involved in suppression of CDH1/E-cadherin transcription via up-regulation of ZFHX1B;Two gastric cancer cell lines were treated with IGF-I to induce EMT and levels of transcription factor ZEB2 and microRNA-200c miR-200c were measured; Furthermore both Akt/ERK inhibitors and knockdown of Akt/ERK gene reversed IGF-I-induced ZEB2 up-regulation and EMT through up-regulation of miR-200c suggesting the involvement of an Akt/ERK-miR-200c-ZEB2 axis in IGF-I-induced EMT
133 hsa-miR-200c-3p ZFHX4 3.5 0 -2.72 0 miRNATAP -0.6 0 NA
134 hsa-miR-200c-3p ZFPM2 3.5 0 -3.3 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.61 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF NEURON DIFFERENTIATION 22 554 1.798e-11 4.183e-08
2 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 38 1672 9.939e-12 4.183e-08
3 CELL DEVELOPMENT 34 1426 4.59e-11 5.723e-08
4 REGULATION OF CELL DEVELOPMENT 26 836 4.919e-11 5.723e-08
5 REGULATION OF CELL DIFFERENTIATION 33 1492 6.631e-10 6.171e-07
6 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 23 750 9.814e-10 7.611e-07
7 POSITIVE REGULATION OF NEURON DIFFERENTIATION 15 306 2.229e-09 1.482e-06
8 POSITIVE REGULATION OF CELL DEVELOPMENT 18 472 2.759e-09 1.605e-06
9 REGULATION OF NEURON PROJECTION DEVELOPMENT 16 408 1.52e-08 7.479e-06
10 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 25 1021 1.607e-08 7.479e-06
11 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 28 1275 2.014e-08 8.519e-06
12 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 16 437 3.952e-08 1.319e-05
13 NEUROGENESIS 29 1402 3.969e-08 1.319e-05
14 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 26 1142 3.459e-08 1.319e-05
15 EXTRACELLULAR STRUCTURE ORGANIZATION 13 304 1.367e-07 4.239e-05
16 REGULATION OF CELL PROJECTION ORGANIZATION 17 558 2.033e-07 5.782e-05
17 REGULATION OF CELLULAR COMPONENT MOVEMENT 20 771 2.113e-07 5.782e-05
18 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 11 232 4.747e-07 0.0001227
19 CELLULAR COMPONENT MORPHOGENESIS 21 900 5.807e-07 0.0001378
20 POSITIVE REGULATION OF CELL DIFFERENTIATION 20 823 5.921e-07 0.0001378
21 TISSUE DEVELOPMENT 28 1518 7.46e-07 0.0001653
22 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 12 303 9.552e-07 0.000202
23 LOCOMOTION 23 1114 1.318e-06 0.0002666
24 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 26 1395 1.655e-06 0.0003209
25 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 12 337 2.887e-06 0.0005374
26 MUSCLE SYSTEM PROCESS 11 282 3.197e-06 0.0005721
27 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 10 229 3.363e-06 0.0005796
28 REGULATION OF CELL MORPHOGENESIS 15 552 4.53e-06 0.0007528
29 FOREBRAIN DEVELOPMENT 12 357 5.208e-06 0.0008077
30 BIOLOGICAL ADHESION 21 1032 5.069e-06 0.0008077
31 RESPONSE TO WOUNDING 15 563 5.744e-06 0.0008622
32 CELL MOTILITY 18 835 1.194e-05 0.001684
33 LOCALIZATION OF CELL 18 835 1.194e-05 0.001684
34 EMBRYONIC MORPHOGENESIS 14 539 1.593e-05 0.00218
35 REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 5 48 1.702e-05 0.002214
36 NEURON PROJECTION DEVELOPMENT 14 545 1.801e-05 0.002214
37 NEURON PROJECTION MORPHOGENESIS 12 402 1.713e-05 0.002214
38 REGULATION OF CELL PROLIFERATION 25 1496 1.808e-05 0.002214
39 TISSUE MIGRATION 6 84 2.141e-05 0.002491
40 CENTRAL NERVOUS SYSTEM DEVELOPMENT 18 872 2.132e-05 0.002491
41 CELL PART MORPHOGENESIS 15 633 2.289e-05 0.002598
42 REGULATION OF PHOSPHORUS METABOLIC PROCESS 26 1618 2.355e-05 0.002609
43 NEGATIVE REGULATION OF CELL PROLIFERATION 15 643 2.743e-05 0.002968
44 EMBRYO DEVELOPMENT 18 894 2.962e-05 0.003132
45 CIRCULATORY SYSTEM PROCESS 11 366 3.662e-05 0.003787
46 REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION 4 29 4.018e-05 0.004064
47 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 13 513 4.188e-05 0.004147
48 MESENCHYME DEVELOPMENT 8 190 4.301e-05 0.004169
49 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 27 1784 4.568e-05 0.004338
50 SYNAPSE ORGANIZATION 7 145 5.548e-05 0.005163
51 NEURON DEVELOPMENT 15 687 5.831e-05 0.00532
52 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 19 1036 6.197e-05 0.005441
53 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 19 1036 6.197e-05 0.005441
54 REGULATION OF MUSCLE TISSUE DEVELOPMENT 6 103 6.789e-05 0.00585
55 NEGATIVE REGULATION OF LOCOMOTION 9 263 7.158e-05 0.006041
56 WOUND HEALING 12 470 7.79e-05 0.006041
57 NEGATIVE REGULATION OF CELL DEATH 17 872 7.467e-05 0.006041
58 NEURON DIFFERENTIATION 17 874 7.679e-05 0.006041
59 CARDIOVASCULAR SYSTEM DEVELOPMENT 16 788 7.697e-05 0.006041
60 CIRCULATORY SYSTEM DEVELOPMENT 16 788 7.697e-05 0.006041
61 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 20 1152 8.317e-05 0.006142
62 HEAD DEVELOPMENT 15 709 8.299e-05 0.006142
63 DIVALENT INORGANIC CATION TRANSPORT 9 268 8.267e-05 0.006142
64 ION TRANSPORT 21 1262 9.892e-05 0.00716
65 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 22 1360 1e-04 0.00716
66 POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 7 162 0.0001115 0.007702
67 CELL PROJECTION ORGANIZATION 17 902 0.0001126 0.007702
68 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 162 0.0001115 0.007702
69 REGULATION OF CELL DEATH 23 1472 0.0001146 0.007731
70 SYSTEM PROCESS 26 1785 0.0001218 0.008004
71 SENSORY ORGAN DEVELOPMENT 12 493 0.0001221 0.008004
72 CALCIUM ION TRANSPORT 8 223 0.0001317 0.008305
73 CELLULAR RESPONSE TO KETONE 5 73 0.0001306 0.008305
74 NEGATIVE REGULATION OF CELL COMMUNICATION 20 1192 0.0001321 0.008305
75 TELENCEPHALON DEVELOPMENT 8 228 0.0001534 0.009517
76 MUSCLE STRUCTURE DEVELOPMENT 11 432 0.0001599 0.009664
77 REGULATION OF DENDRITE DEVELOPMENT 6 120 0.0001581 0.009664
NumGOOverlapSizeP ValueAdj. P Value
NumGOOverlapSizeP ValueAdj. P Value
1 NEURON PART 25 1265 9.455e-07 0.0002355
2 NEURON PROJECTION 21 942 1.21e-06 0.0002355
3 CELL BODY 15 494 1.163e-06 0.0002355
4 SOMATODENDRITIC COMPARTMENT 17 650 1.679e-06 0.0002452
5 SYNAPSE 17 754 1.199e-05 0.0014
6 MEMBRANE REGION 21 1134 2.11e-05 0.002054
7 CELL JUNCTION 21 1151 2.628e-05 0.002193
8 PLASMA MEMBRANE PROTEIN COMPLEX 13 510 3.944e-05 0.002879
9 CELL PROJECTION 27 1786 4.658e-05 0.003022
10 DENDRITE 12 451 5.255e-05 0.003069

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04270_Vascular_smooth_muscle_contraction 7 116 1.316e-05 0.002329
2 hsa04512_ECM.receptor_interaction 5 85 0.0002675 0.02059
3 hsa04540_Gap_junction 5 90 0.0003489 0.02059
4 hsa04971_Gastric_acid_secretion 4 74 0.001542 0.06812
5 hsa04514_Cell_adhesion_molecules_.CAMs. 5 136 0.002237 0.06812
6 hsa04510_Focal_adhesion 6 200 0.002309 0.06812
7 hsa04970_Salivary_secretion 4 89 0.00303 0.07662
8 hsa04912_GnRH_signaling_pathway 4 101 0.004765 0.09371
9 hsa04916_Melanogenesis 4 101 0.004765 0.09371
10 hsa04020_Calcium_signaling_pathway 5 177 0.006844 0.1211
11 hsa04010_MAPK_signaling_pathway 6 268 0.009447 0.152
12 hsa04720_Long.term_potentiation 3 70 0.01161 0.1581
13 hsa04730_Long.term_depression 3 70 0.01161 0.1581
14 hsa04810_Regulation_of_actin_cytoskeleton 5 214 0.0147 0.1859
15 hsa04972_Pancreatic_secretion 3 101 0.03046 0.3595
16 hsa04380_Osteoclast_differentiation 3 128 0.05489 0.5932
17 hsa04360_Axon_guidance 3 130 0.05698 0.5932
18 hsa04920_Adipocytokine_signaling_pathway 2 68 0.07625 0.7498
19 hsa04520_Adherens_junction 2 73 0.08611 0.7574
20 hsa04260_Cardiac_muscle_contraction 2 77 0.09427 0.7574
21 hsa04070_Phosphatidylinositol_signaling_system 2 78 0.09634 0.7574
22 hsa04664_Fc_epsilon_RI_signaling_pathway 2 79 0.09842 0.7574
23 hsa04012_ErbB_signaling_pathway 2 87 0.1155 0.8521
24 hsa04666_Fc_gamma_R.mediated_phagocytosis 2 95 0.1333 0.9017
25 hsa04062_Chemokine_signaling_pathway 3 189 0.1338 0.9017
26 hsa04114_Oocyte_meiosis 2 114 0.1777 1
27 hsa04670_Leukocyte_transendothelial_migration 2 117 0.1849 1
28 hsa04530_Tight_junction 2 133 0.224 1
29 hsa04650_Natural_killer_cell_mediated_cytotoxicity 2 136 0.2314 1
30 hsa04910_Insulin_signaling_pathway 2 138 0.2363 1
31 hsa04310_Wnt_signaling_pathway 2 151 0.2686 1
32 hsa04630_Jak.STAT_signaling_pathway 2 155 0.2785 1
33 hsa00230_Purine_metabolism 2 162 0.2958 1

Quest ID: 596789d323fd20e8ad200ba8e2032ff6